AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 91 min read$SNDX

Metzger Michael A sold $785K of SNDX

Metzger Michael A (Chief Executive Officer) sold 32,375 shares of Syndax Pharmaceuticals Inc (SNDX) at $24.24 ($0.78M total) on 2026-07-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Metzger Michael A
Published Jul 9, 2026, 8:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SNDX
Neutral
high confidence
Mentioned
$SNDX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNDXNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price ($24.2402/share), and post-transaction holdings, with no other company event included.

02

Market read

Traders may note insider selling, but the disclosure lacks fundamental catalysts and is typically low-signal.

03

What to watch

Insider sales under 10b5-1 are often mechanically scheduled; without changes in buying activity or additional disclosures, signal strength is low.

Relevance 4/10Novelty 3/10Timing: as-of the SEC Form 4 filing date (2026-07-09)

Background

The article is an SEC Form 4 insider transaction disclosure for Syndax Pharmaceuticals, filed by CEO Metzger.

Company-level read

Ticker impact

$SNDXNeutralHigh confidence
Context

Syndax CEO Metzger sold 32,375 shares in an open-market transaction worth about $784,776 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades.

Evidence & confidence

The filing is a Form 4 insider transaction with no accompanying company-specific news, guidance, or event described.

Market effects

Sector

No clear read-across to biotech sector fundamentals from a single CEO open-market sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be pre-planned under a 10b5-1 plan and could reflect diversification or tax liquidity rather than bearish expectations.

Key entities

  • issuer
    Syndax Pharmaceuticals Inc

    Company whose CEO reported an open-market sale of shares via Form 4.

  • insider
    Metzger Michael A

    CEO and director who executed the reported sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SNDX insider trading history →

Related articles

OCT 12
$SNDXHighAI 8/10

Syndax Pharmaceuticals stock tumbles on failed IPF trial

Syndax Pharmaceuticals (SNDX) shares dropped 15% after its axatilimab drug failed to meet the primary endpoint in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF). The trial did not show a significant decline in forced vital capacity (FVC). The company will not pursue further IPF development but continues trials for chronic graft-versus-host disease (cGVHD) and other indications.

investing.com2 min
OCT 12
$SNDXMedAI 8/10

A lung-fibrosis drug missed its trial goal. Syndax does not plan to develop it further.

Syndax Pharmaceuticals (SNDX) announced that its Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of reducing lung function decline. The drug was well tolerated but will not be developed further for IPF. Ongoing trials in chronic graft-versus-host disease (cGVHD) continue, with results expected later this year and in early 2028. The company remains focused on advancing axatilimab and revumenib in other indications.

stocktitan.net2 min
AUG 12
$SNDXMedAI 8/10

Syndax (SNDX) Q2 2026 Earnings Call Transcript

Syndax (SNDX) discussed its Q2 2026 earnings call, focusing on menin inhibitor Revuforj and axatilimab-related pipeline. Revuforj net revenue was $55 million, up 12% QoQ, with about 1,500 prescriptions, up 15% QoQ. Niktimvo Q2 net revenue rose to $60 million, up 67% YoY. The company reiterated expectations for Revuforj peak US net revenue above $2 billion.

yahoo.com7 min